Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent

Paclitaxel applied directly to the abluminal surface of a bare metal coronary stent, at a dose density of 2.7 microg/mm2, reduced angiographic indicators of in-stent restenosis without short- or medium-term side effects.